Erlocip 150mg Tablet

Erlotinib 150 mg | EGFR Tyrosine Kinase Inhibitor for Targeted Cancer Therapy

Last Updated: June 28, 2026
Medical Review Status: Reviewed for scientific accuracy
Reviewed By: Pharmaceutical Affairs Team
Review Date: June 28, 2026
Reading Time: 7 min read

Quick Facts

Quick Answer

Erlocip® 150 mg Tablet contains Erlotinib Generic Tarceva , a targeted anti-cancer medicine that inhibits the epidermal growth factor receptor (EGFR). It is prescribed for the treatment of certain patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and, in combination with gemcitabine, for pancreatic cancer. By blocking EGFR signaling, Erlotinib helps slow cancer cell growth and disease progression when used under the supervision of an oncology specialist.

Why Choose Erlocip® 150 mg?

• Targeted EGFR inhibitor with established clinical use
• Oral once-daily treatment
• Used in EGFR-driven non-small cell lung cancer
• May delay tumour progression in appropriate patients
• Internationally recognized targeted therapy
• Supported by oncology treatment guidelines
• Convenient tablet formulation for outpatient care

Erlocip® 150 mg Tablet contains Erlotinib, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor widely used in modern oncology. EGFR is a cell-surface receptor involved in regulating cell growth, survival, and proliferation. Certain cancers, particularly non-small cell lung cancer (NSCLC), depend on abnormal EGFR signaling for continued tumour growth. Erlotinib selectively inhibits this pathway, helping reduce cancer cell proliferation.

Erlocip® is commonly prescribed for patients with locally advanced or metastatic NSCLC and may also be used in combination with gemcitabine for advanced pancreatic cancer where clinically appropriate. Treatment selection is based on tumour characteristics, molecular testing, overall health status, and current oncology guidelines.

Buy Erlocip® 150 mg Tablet online from a trusted pharmaceutical supplier offering authentic oncology medicines, secure ordering, responsive customer support, and dependable product availability. Prescription verification may be required depending on local regulations.

Product Information

Clinical Evidence

Erlotinib has been extensively evaluated in international clinical trials involving patients with advanced non-small cell lung cancer and pancreatic cancer. Clinical studies have demonstrated improved progression-free survival in selected patients, particularly those with EGFR-sensitive disease. International oncology guidelines recommend EGFR-targeted therapies based on tumour molecular profiling and individual patient characteristics. Treatment decisions should always be guided by a qualified oncology specialist.

How it works

Erlotinib selectively blocks the intracellular tyrosine kinase activity of the epidermal growth factor receptor (EGFR). This inhibition prevents activation of signaling pathways responsible for tumour cell proliferation, angiogenesis, invasion, and survival. By interrupting these pathways, Erlotinib slows the growth and spread of susceptible cancer cells while supporting targeted treatment strategies.

• Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
• Metastatic Non-Small Cell Lung Cancer
• EGFR Mutation-Positive Lung Cancer (according to approved indications)
• Advanced Pancreatic Cancer in combination with Gemcitabine
• Targeted Oncology Therapy

Key Clinical Benefits

• Targets EGFR signaling involved in tumour growth
• Convenient once-daily oral therapy
• Helps delay disease progression in eligible patients
• Established role in precision oncology
• Reduces tumour cell proliferation through targeted inhibition
• Supported by international clinical evidence and oncology guidelines